Brief: Mirum Pharmaceuticals Announces Primary Endpoint Met In Vistas Study Of Volixibat In Patients With Primary Sclerosing Cholangitis
04/05/2026 13:05
May 4 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES PRIMARY ENDPOINT MET IN VISTAS STUDY OF VOLIXIBAT IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS MIRUM PHARMACEUTICALS INC - VOLIXIBAT SHOWS 2.72 POINT REDUCTION IN PRURITUS, 1.64 POINT PLACEBO-ADJUSTED (P<0.0001) MIRUM PHARMACEUTICALS INC - PRE-NDA MEETING FOR VOLIXIBAT IN PSC SCHEDULED WITH FDA SUMMER 2026; NDA SUBMISSION PLANNED H2 2026 MIRUM PHARMACEUTICALS INC - VOLIXIBAT SAFETY PROFILE CONSISTENT WITH IBAT INHIBITION; MAINLY GI EVENTS AND ELEVATED LIVER PARAMETERS MIRUM PHARMACEUTICALS INC - EXPECTS TOPLINE DATA FROM VANTAGE PHASE 2B STUDY OF VOLIXIBAT IN PBC IN Q1 2027 Source text: ID:nBw9tm4F5a Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX